Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel Supports Symptoms-Based Endpoint For Community-Acquired Bacterial Pneumonia

This article was originally published in The Pink Sheet Daily

Executive Summary

A means of standardizing what are subjective criteria must be developed, the advisory committee stressed to FDA Nov. 3.

You may also be interested in...

Panel Dives Into Non-Inferiority Margins

Non-inferiority margins have been a tricky issue as antibiotic sponsors strive to show efficacy without large, lengthy and costly trials.

Panel Gives Mixed Reviews To Using Single Trial For Community-Acquired Pneumonia

The Anti-Infective Drugs Advisory Committee's failure to agree on a preferred approval pathway for antibiotics to treat community-acquired bacterial pneumonia opens the door for FDA to offer several options to industry.

FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia

The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts